House 2
You are here:  Home  >  Health Care  >  Current Article

Amgen applies for FDA approval of Blincyto

By   /   Tuesday, February 14th, 2017  /   No Comments

    Print       Email

Thousand Oaks-based Amgen submitted an application for Blincyto to the U.S. Food and Drug Administration, the company announced on Feb. 14.

Amgen aims to gain approval for Blincyto to treat Philadelphia chromosome-positive relapsed or refractory B-cell precursor acute lymphoblastic leukemia.

The drug was previously granted breakthrough therapy designation and accelerated approval in December 2014.

“Acute lymphoblastic leukemia is one of the most aggressive B-cell malignancies, and adult patients who relapse or are refractory to treatment often go through multiple lines of therapy,” said Dr. Sean Harper, executive vice president of research and development at Amgen.

• Contact Alex Kacik at [email protected]

    Print       Email

Leave a Reply

Your email address will not be published. Required fields are marked *

You might also like...

Resonant agrees to sell $7.5 million in stock to Longboard

Read More →